来自Derris robusta (DC.) 的异黄的潜力 班斯. 班斯. 班斯. 对抗α-葡萄糖酶的作用
Pakuna Panbo1, Cholpisut Tantapakul2, Apirak Payaka1
1School of Science, Walailak University, Tha Sala, Nakhon Si Thammarat, 80160, Thailand. apirak.pa@mail.wu.ac.th.
Physical chemistry chemical physics : PCCP
|September 27, 2024
概括
来自Derris robusta的异黄显示出不同程度的α-葡萄糖酶抑制. 分子动力学模拟显示,基替代异黄,如德里斯罗布斯D,有效地与酶结合.
科学领域:
- 植物化学 植物化学
- 酶学 是一种酶学.
- 计算化学计算化学
背景情况:
- 德里斯·罗布斯塔 (Derris robusta) 产生的异黄具有潜在的α-葡萄糖酶抑制活性.
- 这些异黄的抑制功效存在显著差异.
- 缺少对异黄-α-葡萄糖酶相互作用的结构和动态见解.
研究的目的:
- 为了研究异黄与α-葡萄糖酶活性部位的结合机制.
- 阐明控制异黄结合的结构和动态特性.
- 为了确定具有增强的α-葡萄糖酶抑制潜力的关键异黄.
主要方法:
- 用分子动力学 (MD) 模拟来建模异黄-α-葡萄糖酶相互作用.
- 分子力学概括 产生的表面积 (MM/GBSA) 计算评估了结合的自由能量.
- 分析的重点是酶活性部位内的稳定和结合力.
主要成果:
- 含有基替代剂的异黄表现出有利的结合自由能量,表明稳定性提高.
- 德里斯罗布斯D和德鲁在α-葡萄糖酶活性部位中表现出特别强大的稳定性.
- 电静电力被确定为异黄结合的主要机制,除了derrubone.
结论:
- 基替代异黄具有与α-葡萄糖酶结合的有利特性.
- 德里斯罗布斯D和德鲁是抑制α-葡萄糖酶的有希望的候选物.
- 了解结合动态为设计更有效的酶抑制剂提供了基础.
更多相关视频
13:35Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota
Published on: May 23, 2025
210
10:26Author Spotlight: Integrating Biochemical Functions of β-Glucanases and Peroxidase Enzymes in Wheat-RWA Interaction
Published on: July 26, 2024
619
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
01:24Glucagon-like Receptor Agonists
305
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
305
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167